Last reviewed · How we verify

guideline-recommended SoC

Shanghai East Hospital · Phase 3 active Small molecule

This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells.

This drug works by inhibiting the PD-1 receptor, which plays a key role in the immune system's ability to recognize and attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Melanoma.

At a glance

Generic nameguideline-recommended SoC
SponsorShanghai East Hospital
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

By blocking the PD-1 receptor, the drug allows the immune system to recognize and attack cancer cells more effectively, leading to a reduction in tumor growth and spread. This mechanism is thought to be responsible for the drug's anti-tumor effects. The drug's ability to inhibit the PD-1 receptor also leads to a reduction in inflammation and an increase in the production of anti-tumor immune cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: